English
Home > Products > 53-03-2

China 53-03-2 Factory

Reliable top quality and great credit score standing are our principles, which will help us at a top-ranking position. Adhering on the tenet of "quality first, consumer supreme" for 53-03-2,CAS NO 53-03-2,Prednisone API,Prednisone, Sincerely stay up for serving you from the in the vicinity of future. You are sincerely welcome to go to our company to talk company face to face with each other and create long-term co-operation with us!
53-03-2, We believe in establishing healthy customer relationships and positive interaction for business. Close cooperation with our customers has helped us to create strong supply chains and reap benefits. Our products and solutions have gained us widespread acceptance and the satisfaction of our worldwide valued clients.

Related Products

Hot Products

  • 4-(4-Amino-3-fluorophenoxy)-N-methylpicolinamide

    4-(4-Amino-3-fluorophenoxy)-N-methylpicolinamide

    Product Name:4-(4-Amino-3-fluorophenoxy)-N-methylpicolinamide
    Molecular Formula:C13H12FN3O2
    Molecular Weight:261.25
    CAS Registry Number:757251-39-1
  • Sodium bicarbonate

    Sodium bicarbonate

    Product Name:Sodium bicarbonate
    Molecular Formula:CHNaO3
    Molecular Weight:84.01
    CAS Registry Number:144-55-8
  • Entrectinib

    Entrectinib

    Product Name:Entrectinib
    Molecular Formula:C31H34F2N6O2
    Molecular Weight;560.64
    CAS Registry Number;1108743-60-7
  • 3,4,5-Trifluorophenol

    3,4,5-Trifluorophenol

    Product Name:3,4,5-Trifluorophenol
    Molecular Formula:C6H3F3O
    Molecular Weight:148.08
    CAS Registry Number:99627-05-1
  • 3,5-Difluoropyridine-2,6-diamine

    3,5-Difluoropyridine-2,6-diamine

    Product Name:3,5-Difluoropyridine-2,6-diamine
    Molecular Formula:C5H5F2N3
    Molecular Weight:145.11
    CAS Registry Number:247069-27-8
  • DL-Alanine

    DL-Alanine

    Product Name:DL-Alanine
    Molecular Formula:C3H7NO2
    Molecular Weight;89.09
    CAS Registry Number;302-72-7
  • Related Blog
  • Reviews

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • What is Coenzyme Q10 CAS NO.303-98-0

    Coenzyme Q10 (CAS NO.303-98-0 ) is a fat-soluble antioxidant, which can activate the nutrition of human cells and cellular energy, and has the functions of improving human immunity, enhancing antioxidation, delaying ageing and enhancing human vitality.

  • What are the raw materials required for pharmaceutical industry?

    Pharmaceutical industry has a lot of constraints and specialties which make it stand on a completely differents scale than any other industries. Being closely related to the medical field and also complementary to it, the pharmaceutical industry needs utmost care and precision in each and every aspect of the field ranging from collecting the raw materials to getting the final product ready for supply in the market.

  • What Is Ursodeoxycholic Acid Used For?

    Ursodeoxycholic acid is a cholelithiant commonly used in the gastroenterology department, and also a cholelithiasis dissolving agent, so it can be used in the treatment of gallstones under normal circumstances, on the premise...

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Related Search

CAS NO 53-03-2

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept